Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of Intranasal CG-SpikeDown in Healthy Volunteers and COVID-19 Patients
NCT05234320Phase 1Unknown
- Sponsor
- Caregen Co., Ltd.
- Start
- Oct 2022
- Primary completion
- Jan 2023
- Modality
- Peptides, Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of CG-SpikeDown in coronavirus disease 2019 (COVID-19), sponsored by Caregen Co., Ltd. Primary endpoints: SARS Cov-2 RT-PCR test at 7 days and Area under the plasma concentration versus time curve at 7 days. Status: unknown.
02
Drugs
CG-SpikeDown
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05234320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05234320.